ClinicalTrials.gg
Not yet recruitingNCT07403877TORCH-OPTIMAUpdated Feb 11, 2026

Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer

A Phase 2 interventional study of Nivolumab and Ipilimumab (1mg/kg) in Colorectal Cancer (MSI-H), sponsored by Fudan University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 38 studies testing nivolumab in Colorectal Neoplasms — 7 open to participants now, 13 under way, 1 of them phase 3. Nivolumab · Colorectal Neoplasms.

Planned enrollment
12th of 38
114 · median 49
Started
2026
with 1 other
Phase 2
23 of 38
7 open now
Primary completion
2031-12
later than 12 of 12 live
Registered
35th of 38
by date

Among the 38 studies testing nivolumab in Colorectal Neoplasms, this one is the 12th largest by planned enrollment, is one of 2 that started in 2026, is one of 23 in phase 2, reaches primary completion later than 12 of the 12 other live ones, and was the 35th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 38 studies testing nivolumab in Colorectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing nivolumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This phase II clinical trial evaluates the efficacy and safety of three neoadjuvant regimens in patients with locally advanced microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC): 1) Regimen A: Dual immune checkpoint blockade with nivolumab plus ipilimumab. 2) Regimen B: Nivolumab plus radiotherapy. 3) Regimen C: Nivolumab monotherapy. The primary objectives are to determine whether: 1) Dual immune checkpoint blockade (Regimen A) is superior to nivolumab monotherapy (Regimen C); and 2) Immunotherapy plus radiotherapy (Regimen B) is superior to nivolumab monotherapy (Regimen C). Methods: Participants will be randomized in a 1:1:1 ratio to one of the three arms. For patients with resectable tumors, surgical resection will be performed. In patients with low rectal cancer and poor prospects for sphincter preservation, a watch-and-wait (WW) strategy is an option if a clinical complete response (CR) is achieved following neoadjuvant therapy.

03

Conditions studied

  • Colorectal Cancer (MSI-H)

Keywords

  • colorectal cancer
  • microsatellite instability high
  • mismatch repair-deficient
  • neoadjuvant therapy
  • radiotherapy
  • immunotherapy
  • locally advanced
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histopathologically confirmed primary colorectal adenocarcinoma.
  2. Radiographic assessment showed a stage II-III based on AJCC Stage 8th ed.
  3. At least 18 years old.
  4. MSI-H or dMMR.
  5. The performance status (ECOG PS) score is 0 or 1.
  6. Physical state or organ function can tolerate the planned treatment of the study protocol.
  7. Agreed to sign written before recruitment.

Exclusion criteria

Exclusion Criteria:

  1. Previously received any antitumor therapy for the disease under study, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.
  2. Pregnancy or breastfeeding women.
  3. History of other within 5 years.
  4. Serious medical illness, such as severe mental disorders, cardiac disease, uncontrolled infection, etc.
  5. Immunodeficiency disease or long-term using of agents.
  6. Allergic to any component of the therapy.
  7. Any other condition or disease that is not suitable to take the therapy included in the protocol.
  8. Concurrent participation in another clinical study, unless participating in an observational (non-interventional) clinical study or in the survival follow-up phase of an interventional study.
  9. Received any drug or device treatment within 4 weeks prior to initial administration of the investigational drug.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    anti-PD-1 plus anti-CTLA-4

    Arm A: Nivolumab 240 mg every 2 weeks (6 doses) plus ipilimumab 1 mg/kg every 3 weeks (4 doses).

    Drug: Nivolumab · Drug: Ipilimumab (1mg/kg) · Procedure: Radical surgery · Other: Watch & wait

  • Experimental
    anti-PD-1 plus radiotherapy

    Arm B: Radiotherapy (5 Gy per fraction, total 4 fractions, delivered every 3 weeks) to the primary lesion plus nivolumab 240 mg every 2 weeks (6 doses).

    Drug: Nivolumab · Radiation: PULSAR · Procedure: Radical surgery · Other: Watch & wait

  • Active comparator
    anti-PD-1 monotherapy

    Arm C: Nivolumab 240 mg every 2 weeks (6 doses).

    Drug: Nivolumab · Procedure: Radical surgery · Other: Watch & wait

Interventions

  • Nivolumab 240 mg every 2 weeks

  • DrugIpilimumab (1mg/kg)

    Drug page: IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ipilimumab 1 mg/kg every 3 weeks

  • RadiationPULSAR

    Irradiation targeted to the primary lesion (5 Gy per fraction, total 4 fractions, delivered every 3 weeks).

  • ProcedureRadical surgery

    Surgical resection will be performed in resectable cases.

  • OtherWatch & wait

    For patients with low rectal cancer who are unable to preserve the anal sphincter, a watch-and-wait (WW) strategy can be considered if a clinical complete response (CR) is achieved.

06

What researchers measure

Primary outcomes

  1. Complete regression (CR) rate

    Proportion of patients achieving either clinical CR (and undergoing WW) or pathological CR (confirmed by pathology) among all evaluable patients.

    Time frame: 1 month after surgery or the completion of neoadjuvant therapy

Secondary outcomes

  1. R0 resection rate

    Proportion of patients who achieve R0 resection.

    Time frame: 1 month after surgery

  2. Objective response rate (ORR)

    Proportion of patients with complete response (CR) or partial response (PR) to preoperative multimodal therapy. ORR will be evaluated using RESIST1.1 by CT/MRI of the chest, abdomen, and pelvis.

    Time frame: 6 months after the enrollment of the last subject

  3. Event-free survival (EFS)

    The EFS was defined as the time from randomization to the first determination of inoperable disease progression, postoperative local recurrence or distant metastasis, tumor regrowth, or death from any cause, whichever occurs first.

    Time frame: 36 months after the enrollment of the last subject

  4. Overall survival (OS)

    OS is defined as the time interval from enrollment to death of any reason or censoring.

    Time frame: 36 months after the enrollment of the last subject

  5. Toxicities

    Number of participants with treatment-related adverse events (TrAEs) reported between the first dose and 28 days after the last dose of study therapy as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

    Time frame: From the time of enrollment, assessed up to 28 days after the last dose of study therapy

  6. Surgical morbidity

    Surgery related adverse events (SRAEs) refer to complications which happen during or one month after surgery. Severe complications after surgery will be documented and classified by Clavien-Dindo classification, such as abdominal or GI tract bleeding, anastomotic fistula, pancreatic fistula of grade B or above, and incision complications (infection, bleeding, rupture).

    Time frame: During or one month after surgery

  7. Surgical mortality

    Death from any cause within 30 days of the date of surgery will be considered a surgical mortality death.

    Time frame: During or one month after surgery

07

Study locations

1 site
  • Fudan University Shanghai Cancer Center
    Shanghai, China
    • Menglong Zhou, MD · Contactmrzhouml@163.com · 86-18121299608
    • Sanjun Cai, MD · Principal investigator
    • Zhen Zhang, MD · Principal investigator
    • Fangqi Liu, MD · Sub investigator
    • Fan Xia, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Dec 2031, 70 months later.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 70 months is above that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2026
First posted
Feb 11, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2034
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07403877
Lead sponsor
Fudan University
Responsible party
Zhen Zhang (Professor, Chief Physician, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University) — Principal investigator
First posted
Feb 11, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2034 (estimated)
Last update
Feb 11, 2026

Study contacts

Menglong Zhou, MD
Contact
mrzhouml@163.com
86+18121299608

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion